EchoIQ

Echo IQ is an AI-driven clinical decision support company that analyzes routine echocardiographic measurements to support fast, consistent interpretation of echocardiograms.

Our first product, EchoSolv, is an AI platform that analyzes echocardiographic measurements to generate a probability assessment of severe aortic stenosis.

EchoSolv‚Ñ¢ AS was built using more than 200 million echocardiographic measurements from real-world patient data, drawn from one of the largest echo datasets in the world. It also delivers strong rule-out performance, with a 99.2% negative predictive value.

Importantly, EchoSolv‚Ñ¢ AS goes beyond current clinical guidelines, identifying high-risk patients who traditional criteria can miss but who show similar five-year mortality to guideline-defined severe AS. For example, in a multi-center study, clinicians initially identified 218 patients with severe AS, while EchoSolv‚Ñ¢ AS found an additional 66 cases with elevated severe AS probability outside current guideline criteria.

It is FDA-cleared as a Class II medical device (510(k) K241245).

Echo IQ's long-term vision is to expand this measurement-based AI platform to support interpretation of additional structural heart diseases.

309 George Street, Suite 404, Sydney, New South Wales 2000, AU